Odyssey Health, Inc. Stock

Equities

ODYY

US67612C1027

Delayed OTC Markets Other stock markets 10:02:18 2024-05-07 EDT			5-day change	1st Jan Change
0.037 ^USD	-1.60%		-3.90%	-63.00%

03-22	Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
2023	Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	CI

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Financials

Sales 2022	-	Sales 2023	-	Capitalization	11.06M 15.18M
Net income 2022	-8M -10.98M	Net income 2023	-5M -6.86M	EV / Sales 2022	-
Net Debt 2022	1.46M 2M	Net Debt 2023	2.11M 2.89M	EV / Sales 2023	-
P/E ratio 2022	-1.99 x	P/E ratio 2023	-1.95 x	Employees	6
Yield 2022 *	-	Yield 2023	-	Free-Float	0%

More Fundamentals * Assessed data

Chart Odyssey Health, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Odyssey Health, Inc.

Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	03-22	CI
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	12-27	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	12-15	CI
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	23-10-30	CI
Odyssey Health, Inc. Announces the Resignation of John Gandolfo as Director	23-10-06	CI
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	23-10-04	CI
Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS	23-08-23	CI
Odyssey Health, Inc. executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.	23-06-27	CI
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-14	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-17	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-17	CI
Odyssey Health, Inc. Appoints Jeffrey Conroy as Director	23-01-13	CI
Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote	23-01-12	CI
Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director	23-01-06	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	22-12-14	CI

More news

Press releases Odyssey Health, Inc.

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate	23-10-06	AQ
AM Best Upgrades Credit Ratings of Odyssey Group Holdings, Inc.'s Members	23-07-07	AQ
ODYSSEY HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	23-04-04	AQ
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment	23-03-30	AQ
ODYSSEY HEALTH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	23-03-17	AQ